InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
5,826.82
(
0.20%
)
US TECH 100
19,573.67
(
-0.31%
)
Dow Jones
42,989.81
(
0.58%
)
Brent Oil
74.01
(
-0.62%
)
Bitcoin
67,840.76
(
1.24%
)
Post# of 80490
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

biomaven0

Send PM Follow Ignore
Followers 82
Posts 4778
Boards Moderated 0
Alias Born 02/27/2007

biomaven0

Re: rkrw post# 9784

Thursday, 06/23/2011 10:55:27 PM

Thursday, June 23, 2011 10:55:27 PM

Post# of 80490
Interesting:

By inhibiting both T790M and the initial activating mutations, Avila drug candidates in the EMSI program offer the prospect of effective drug treatment for first and second-line NSCLC patients who have activating EGFR mutations. With sparing of the wild-type EGFR, the EMSI program could also offer a much improved therapeutic window (i.e. fewer side effects) compared to current therapies in a first-line setting.

Avila is the company with a BTK drug competitive with PCYC.

Peter
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next
Join InvestorsHub

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up